Overview of Liver Disease Syndromes
Liver disease is best organized by clinical syndrome (acute liver failure, chronic hepatitis, cholestatic disease, cirrhosis with portal hypertension, and focal liver tumors).
Cirrhosis is a unifying endpoint of multiple etiologies and predicts complications including ascites, variceal hemorrhage, hepatic encephalopathy, infection, and hepatocellular carcinoma (HCC). [1]
Etiology-Based Categories
Common chronic etiologies include viral hepatitis (hepatitis B virus [HBV] and hepatitis C virus [HCV]), metabolic dysfunction–associated steatotic liver disease (MASLD/NAFLD), alcohol-associated liver disease, autoimmune hepatitis, cholestatic disorders (primary biliary cholangitis and primary sclerosing cholangitis), and inherited metabolic diseases. [2]
Diagnostic Approach for Suspected Liver Disease
Initial evaluation focuses on determining the pattern of liver injury (hepatocellular vs cholestatic) and the chronicity (acute vs chronic).
A medication and toxin review is required, because drug-induced liver injury and herbal/supplement exposures can mimic viral or autoimmune hepatitis.
Serum liver biochemistries should be interpreted as patterns rather than single values, because the same absolute ALT/AST value can correspond to different etiologies depending on alkaline phosphatase and bilirubin.
Staging and Prognosis in Chronic Liver Disease
Assessment of fibrosis stage guides prognosis and cancer/portal hypertension surveillance intensity.
Noninvasive risk stratification for portal hypertension is used in cirrhosis to guide endoscopy and preventative therapy decisions. [3]
Cirrhosis With Portal Hypertension: Core Complications
Hepatic decompensation is commonly defined by ascites, hepatic encephalopathy, and portal hypertensive gastrointestinal bleeding. [1]
Ascites, Spontaneous Bacterial Peritonitis, and Hepatorenal Syndrome
Ascites evaluation includes diagnostic paracentesis to assess for spontaneous bacterial peritonitis (SBP). [1]
Hepatorenal syndrome is approached as a complication of advanced cirrhosis with renal hypoperfusion physiology and should be differentiated from intrinsic kidney disease. [1]
Portal Hypertensive Bleeding and Varices Prevention
Risk stratification for clinically significant portal hypertension is used to guide prophylaxis and surveillance intensity in cirrhosis. [3]
Pharmacologic prophylaxis and endoscopic strategies are used to prevent first and recurrent variceal hemorrhage, with escalation to procedural rescue therapy for bleeding. [3]
Interventional radiology techniques such as TIPS and related procedures are incorporated for selected cases of variceal hemorrhage. [4]
Hepatic Encephalopathy
Hepatic encephalopathy (HE) is approached as a clinical syndrome related to liver dysfunction and portosystemic shunting.
Ammonia testing is not used as the primary diagnostic anchor because increased ammonia alone does not add diagnostic/staging/prognostic value for HE in chronic liver disease. [5]
HE management includes identifying and treating precipitating factors and using therapies that reduce neurotoxic burden. [6]
Hepatocellular Carcinoma Prevention and Surveillance
Patients with cirrhosis are managed with structured HCC surveillance strategies because early detection enables curative or life-prolonging therapy. [7]
Risk stratification and selection of diagnostic imaging and treatment modalities are addressed in AASLD HCC guidance. [7]
Viral Hepatitis Management (HBV and HCV)
HCV infection is treated with direct-acting antivirals (DAAs), with updated testing and management guidance provided by AASLD/IDSA. [8]
Universal HCV screening is recommended in AASLD/IDSA guidance based on cost-effectiveness and improved case finding enabled by antiviral therapy availability. [8]
Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD/NAFLD)
NAFLD/MASLD evaluation includes identifying steatosis, excluding other causes of chronic liver injury, and staging fibrosis to determine risk and intensity of follow-up. [2]
Metabolic comorbidity management is incorporated into NAFLD/MASLD care because cardiovascular risk is a leading determinant of outcomes in this population. [2]
Liver Transplantation and End-Stage Disease Escalation
Referral for liver transplantation evaluation is triggered by cirrhosis complications and worsening prognosis and is guided by transplant candidate evaluation frameworks. [9]
Adult liver transplant candidate evaluation includes multiorgan assessment, cardiopulmonary evaluation, frailty and psychosocial evaluation, and specific consideration of contraindications and tumor criteria when relevant. [10]
Palliative Care in Decompensated Cirrhosis
Palliative care and symptom-based management are included as part of standard care planning in decompensated cirrhosis, alongside disease-directed therapies. [11]
Practical Clinical “Everything” Coverage Checklist
Key laboratory evaluation domains include hepatic injury pattern (ALT/AST, alkaline phosphatase, bilirubin), synthetic function (INR, albumin), and systemic complications (CBC and renal function).
Key procedural evaluation domains include diagnostic paracentesis for ascites when clinically indicated and endoscopic assessment for varices based on risk stratification. [1] [3]
Key long-term domains include HCC surveillance in appropriate patients, antiviral therapy in viral etiologies, fibrosis risk stratification in metabolic etiologies, and transplant pathway identification when decompensation occurs. [7] [2] [8] [9]